ERBB2 and tumor of salivary gland: Trastuzumab monotherapy, trastuzumab and pertuzumab, trastuzumab with docetaxel, and T-DM1 are recommended for use in HER2-positive salivary gland tumors, and T-DXd can be considered as an option [153].